Evidence map›Paper›PMID 40934374›Full record

ArticleAntimicrobial agents and chemotherapy2025

Preclinical evaluation of tridecaptin M:

Vrushali Raka, Manoj Jangra, Parminder Kaur, Rajneesh Dadwal, Shubhangi Kansal, Archana Angrup, Pallab Ray, Hemraj Nandanwar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vrushali RakaClinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India.ORCID 0000-0002-2518-0015
Manoj JangraClinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India.
Parminder KaurClinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India.
Rajneesh DadwalClinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India.
Shubhangi KansalDepartment of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.ORCID 0000-0001-8633-3348
Archana AngrupDepartment of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Pallab RayDepartment of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Hemraj NandanwarClinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India.ORCID 0000-0003-4301-6355

Funding

Council of Scientific and Industrial Research, India FTT_MLP- 038
6 · The paper itself

Abstract

The escalating threat of antimicrobial resistance (AMR), particularly among gram-negative pathogens, necessitates the development of novel therapeutic agents. Tridecaptins, a class of non-ribosomally synthesized lipopeptides with a novel mode of action, have garnered renewed interest in the fight against AMR. Our group previously identified tridecaptin M, a compound with a promising safety profile, prompting further investigation into its efficacy and preclinical characteristics. Here, we show that tridecaptin M exhibits potent activity against multidrug-resistant (MDR)

Indexed as

Anti-Bacterial AgentsColistinEscherichia coliKlebsiella pneumoniaeLipopeptidesAnimalsBiofilmsDrug Resistance, Multiple, BacterialFemaleGram-Negative BacteriaKlebsiella InfectionsMaleMiceMicrobial Sensitivity TestsRatsRats, Sprague-DawleyAnti-Bacterial AgentsColistinLipopeptidesAMPscolistin-resistant Klebsiella pneumoniaegram-negative bacteriamultidrug-resistantpharmacokineticspreclinicaltridecaptins

Identifiers

PMID40934374
PMCPMC12486805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.